265 Incidence, determinants and prognostic relevance of HS-troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients

Luca Arcari¹, Michelangelo Luciano¹, Luca Cacciotti¹, Maria Beatrice Musumeci², Valerio Spuntarelli³, Eleonora Pietella¹, Dario Martolini¹, Daniele Manzo¹, Maristerea Pucci¹, Claudio Marone¹, Serena Melandri², Gerardo Assalone¹, Claudio Santini¹, Paolo Martelletti³, Massimo Volpe¹ and Luciano De Biase⁴

¹Unità di Cardiologia, Ospedale Madre Giuseppina Vannini, Roma, ²Unità di Medicina Interna, Ospedale Madre Giuseppina Vannini, Roma, ³Unità di Medicina Interna, Facoltà di Medicina e Psicologia, Sapienza Università di Roma, ⁴Unità Scompenso Cardiaco, Facoltà di Medicina e Psicologia, Sapienza Università di Roma.

Aims: myocardial involvement in the course of Coronavirus disease 2019 (COVID-19) pneumonia has been reported, though not fully characterized yet. Aim of the present study is to undertake a joint evaluation of hs-Troponin and natriuretic peptides (NP) in patients hospitalized for COVID-19 pneumonia.

Methods and results: in this multicenter observational study, we analyzed data from n = 111 COVID-19 patients admitted to dedicated “COVID-19” medical units. HS-Troponin was assessed in n = 103 patients and NP in n = 82 patients on admission; subgroups were identified according to values beyond reference range. Increased hs-Troponin and NP were found in 38% and 56% of the cases respectively. As compared to those with normal cardiac biomarkers, these patients were older, had higher prevalence of cardiovascular diseases (CVD) and more severe COVID-19 pneumonia by higher CRP and D-dimer and lower PaO2/FIO2. Two-dimensional echocardiography performed in a subset of patients (n = 24) showed significantly reduced left ventricular ejection fraction in patients with elevated NP only (p < 0.02), whereas right ventricular systolic function (tricuspid annular plane systolic excursion) was significantly reduced both in patients with high hs-Troponin and NP (p < 0.02 and p < 0.03 respectively). On multivariate analysis, independent associations were found of hs-Troponin with age, PaO2/FIO2 and D-dimer (B = 0.419, p < 0.001; B = 0.212, p = 0.013 and B = 0.179, p = 0.037 respectively), and of NP with age and previous CVD (B = 0.480, p < 0.001 and B = 0.253, p < 0.001 respectively). In patients with in-hospital mortality (n = 23, 21%) hs-Troponin and NP were both higher (p = 0.001 and p = 0.002 respectively), while increasing hs-troponin and NP were associated with worse in-hospital prognosis (OR 4.88 [95% CI 1.9.12-2.2], p = 0.001 [adjusted OR 3.1 [95% CI 1.2.8-3.2], p = 0.025] and OR 4.67 [95% CI 2.10-8.0], p = 0.001 [adjusted 2.89 [95% CI 1.7.7-9.2], p = 0.04] respectively). Receiver operator characteristic curves showed good ability of hs-Troponin and NP in predicting in-hospital mortality (AUC = 0.869, p = 0.001 and AUC = 0.810, p = 0.001 respectively).

Conclusion: myocardial involvement at admission is common in COVID-19 pneumonia and associated to worse prognosis, suggesting a role for cardiac biomarkers assessment in COVID-19 risk stratification. Independent associations of hs-Troponin with markers of disease severity and of NP with underlying CVD might point towards existent different mechanisms leading to their elevation in this setting.

257 Percutaneous urgent treatment of severe aortic stenosis in a patient during SARS-CoV2 pandemic: role of balloon aortic valvuloplasty

Tiziana Attitano¹, Angelo Silviero², Michele Bellino³, FrancescaMaria Di Muro¹, Cesare Balsi¹, Enrico Coscin³, Gennaro Galasso¹,² and Carmine Vecchione²

¹Interventional Cardiology Unit Cardiovascular and Thoracic Department Aou S. Giovanni di dio E Ruggi D’aragona Salerno Italy, ²University Cardiology Unit Aou S. Giovanni di dio e Ruggi D’aragona Salerno Italy and ³Cardiothoracic Surgery Unit Cardiovascular and Thoracic Department Aou S. Giovanni di dio e Ruggi D’aragona Salerno Italy.

Aims: The majority of transcatheter aortic valve implantation (TAVI) procedures are performed on an elective basis and, therefore, have been postponed during Coronavirus disease 2019 (COVID-19) outbreak. However, delay in the treatment of severe aortic stenosis (AS) may increase the risk of adverse events, particularly in elderly patients with multiple comorbidities.

Methods and results: An 86-year-old man, affected by severe AS was referred to our Institution from a spoke centre due to decompensated heart failure refractory to optimal medical therapy. Three months before, the patient was evaluated by our Heart Team and was scheduled for TAVI. Since that time, he had been waiting for elective TAVI procedure, which was postponed due to the COVID-19 outbreak sparked.
507 Impact of the COVID-19 pandemic on clinical outcomes of ACS: a retrospective analysis from a cardiology network in Abruzzo, Central Italy

Lorenzo Belli, Matteo De Rosa, Antonio Oliva, Simone Grassi, Marcello Caputo, Cristian Dodi, Pisare Fontamerrando, and Jacopo Pizzica

Aims: The reorganization of healthcare services due to the COVID-19 pandemic has radically changed the management of inpatients and outpatients affected by cardiovascular disorders. Moreover, several authors worldwide have reported a significant decrease in hospital admissions for acute coronary syndromes (ACS) during the most recent months of the COVID-19 outbreak. To prepare for a second wave of the pandemic, the causes of this pattern and its impact on patients and hospital management have been studied.

Methods and results: We conducted a monocentric, observational, retrospective study aimed at evaluating consecutive patients discharged from our local network with a diagnosis of ACS from the 20th of February 2020 to the 30th of April 2020. A total of 201 patients with ACS were included in the analysis. All patients with ACS in 2020 were free of Sars-cov2 infection. Seventy-two ACS cases occurred during the February 20-April 30, 2020 period, while 129 were recorded in the same period of 2019 (44.4% reduction). In particular, the number of patients with NSTE (Non-ST-elevation) ACS dropped from 84 (65%) in 2019 to 21 (44.4%) in 2020 (62% reduction, p = 0.01), while more patients with a diagnosis of STEMI (ST elevation myocardial infarction) were admitted in 2020. Thirty-eight composite events (mortality, life-threatening arrhythmias, mechanical complications and acute heart failure) were observed in 2020, while only 34 patients were free from events. Conversely, in the 2019 ACS group, 37 events were recorded, while 92 patients did not develop any events (RR 1.82; 1.29-2.6 95% CI; p = 0.01).

Conclusion: It is still matter of debate why the incidence of ACS has decreased during COVID-19 pandemic, and the fear of seeking medical aid in high-risk environments such as hospitals has been proposed as a possible explanation. However, the delay in diagnosis and treatment of these patients has a significant impact on public health costs and sustainability of care, since delayed diagnosis has been shown to be associated with a significant increase in short-term complications and deaths. Public health messaging and proper healthcare services organization should play a crucial role in adjusting the system to the new needs of public health.

360 In-hospital cardiovascular evaluation of COVID-19 patients during SARS-CoV-2 pandemic: results from a systematic approach

Lucia Ilaria Birtolo, Viviana Maestrini, Nicola Galea, Paolo Severino, Fabio Infrusino, Gioacchino Galardo, Giancarlo Cecarelli, Francesco Alessandrini, Peppe Palange, Maria Chiara Colasacco, Claudio M Mastroianni, Cristina Chimenti, Andrea Frustaci, Gabriella Dettorre, Franco Ruberto, Carlo Catalano, Francesco Pugliese, Marco Francone, Massimo Mancone, and Francesco Fedele

Aims: An increasing number of evidences, limited to sporadic cases or to echocardiography evaluation, reported that cardiovascular involvement is common in COVID-19 patients. Aim of this study was to assess the occurrence of cardiovascular diseases (CD) in confirmed COVID-19 patients admitted to hospital by clinical evaluation focusing on patients with acute coronary syndromes (ACS) and STEMI, and in those treated during the COVID-19 pandemic.

Methods and results: During an interval time of 30 days, n = 76 consecutive confirmed COVID-19 patients were undergone to cardiovascular evaluation within 48 hours from admission to our hospital. Twelve-standard electrocardiogram (ECG), high-sensitive Troponin and FoCUS evaluation by portable ultrasound were performed integrated by further examinations when indicated.

Conclusion: In-hospital cardiovascular evaluation of COVID-19 patients during SARS-CoV-2 pandemic should be performed during the COVID-19 pandemic due to the high morbidity and mortality associated with cardiovascular disease.
the hospitalization for COVID-19. On the overall cohort 28% had CD. A final diagnosis was reached in 13 patients: acute myocarditis (n = 7) and pericarditis (n = 2), acute pulmonary embolism (n = 2), Takotsubo’s syndrome (n = 1), myocardial infarction (n = 1). Ventricular dysfunction was identified in other 8 patients but further test could not be performed due to instability/condition/death, acute renal failure, patients refusal. Death occurred more often in patients presenting with CD compared to patients without CD (29% vs. 5%, p = 0.011).

Conclusion: Systematic cardiac evaluation during hospitalization for COVID-19 revealed the occurrence of a wide spectrum of cardiovascular conditions. Death occurred more often in patients with cardiovascular condition. FoCUS scan was easy and quick to perform and useful to screen patients requiring further test.

467 Aggressive, multisite vascular complications in COVID-19 Infection: a case report
Andrea Boccadottoli,1 Damiano Dardes,1 Giulio Cocco,2 Cosima Schiavone,1 Maria Teresa Guagnano,1 Francesca Santilli,1 Marco Buccì,1 Gianfranco Lessiani1,1 and Francesco Cipollone1
1Università degli Studi G.D’Annunzio Chieti-Pescara

Aims: COVID-19 has relevant cardiovascular implications, and patients with previous cardiovascular disease display an higher risk for detrimental outcomes. Methods and results: A 68-years old female patient was admitted to the emergency department complaining fever (38°C) for seven days, dyspnoea and neurological deficit (aphasia and hemiplegia). Her past medical history was characterized by hypertension, bilateral carotid and mild peripheral artery disease (PAD). Home drug therapy was: aspirin and beta-blocker. Chest X-ray showed an infiltrative opacity and interstitial thickening prevalent on the inferior left lung. A nasopharyngeal swab was obtained resulting positive for Sars-CoV-2. Head CT showed acute lacunar infarction in the temporal right region. The day after, an electrocardiogram showed a posterolateral myocardial infarction (MI) with ST elevation (STEMI) for monovasal arterial occlusion which required urgent intervention (percutaneous coronary intervention (PCI) using drug-eluting stents (DES) on circonflex coronary artery). Blood tests showed: myoglobin 449.0 ng/mL; Hs-troponin I 2406.0 pg/mL; aPTT 37 SEC.; PT/INR 0.9 echocardiographic examinations. ACP was diagnosed in 23/27 (61%) patients with COVID-19 related ARDS. Mortality was significantly higher in patients with ACP than in the other patients (p = 0.048). During the follow-up, we did not observe any further ACP onset or worsening right ventricular function in non-ACP patients. Conclusion: Transthoracic echocardiography may reveal ACP in a sizeable proportion of patients with COVID-19 related ARDS. In our cohort, ACP was associated with higher blood levels of D-dimer and troponin on ICU admission and with higher 30-days mortality as compared with ARDS patients without ACP.

552 Acute COR pulmonale in a cohort of patients with COVID-19 related acute respiratory distress syndrome
Giulio Cacciol1, Michele Ciabatti2, Damiano Magni1, Antonella Romaniello1, Maurizio Pierioni1, Leonardo Bolognese2, Massimo Volpe1, and Camillo Autore1
1Divisione di Cardiologia, Dipartimento di Medicina Clinica e Molecolare, Facoltà di Medicina e Psicologia, La Sapienza, Roma, 2Divisione di Cardiologia, Ospedale San Donato, Arezzo

Aims: COVID-19 is often characterized by severe hypoxemia, regardless of respiratory system compliance, high rate of pulmonary thromboembolism and diffuse thrombosis of pulmonary microcirculation at necropsy. Although these mechanisms can conspire to determine rapid onset of right ventricle (RV) overload and failure, the impact of acute cor pulmonale (ACP) in severe COVID-19 is still unclear.

Methods and results: Between March 27 and April 23, 2020 all patients hospitalized in our ICU with COVID-19 related acute respiratory distress syndrome (ARDS) underwent systematic echocardiographic evaluations. The presence of RV overload and paradoxical movement of the interventricular septum defined ACP. At every time point of examination we collected all available clinical, laboratory and respiratory parameters and evaluated potential association with ACP. We enrolled 27 consecutive patients (59% males), mean age 69 ± 13 years. The first trans-thoracic echocardiogram was performed at a median time from ICU admission of 6 days. Mean ICU stay was 22 ± 16 days. Each patient underwent a mean of 2.4 ± 0.9 echocardiographic examinations. ACP was diagnosed in 7/27 (26%) at first echocardiographic evaluation. At univariate analysis, elevated plasma D-dimer (OR 1.41, 95% CI 1.02-1.94; p = 0.04) and troponin (OR 1.21, 95% CI 1.04-1.40; p = 0.01) on ICU admission presented significant association with ACP. During the 30-days follow-up, 7/27 (26%) patients died, 4/7 (57%) with ACP and 3/20 (15%) without ACP. Mortality was significantly higher in patients with ACP than in the other patients (p = 0.048). During the follow-up, we did not observe any further ACP onset or worsening right ventricular function in non-ACP patients. Conclusion: Transthoracic echocardiography may reveal ACP in a sizeable proportion of patients with COVID-19 related ARDS. In our cohort, ACP was associated with higher blood levels of D-dimer and troponin on ICU admission and with higher 30-days mortality as compared with ARDS patients without ACP.

568 STEMI in lockdown period: first outcomes from Italian real world COVID-19
Michela Bonanni1, Andrea Bezzeccheri1, Martino Balingi,1 Enrichetta Dato1, Saverio Muscoli1, Daniela Benedetto1, Giuseppe Stifano1, Massimiliano Macrini1, Alessio Di Landro1, Marco Di Luozzo1, Massimo Marchei1, Enrica Giuliana Mariano1, Linda Cota1, Francesco Romeo1, and Valeria Cammalleri1
1OIC Cardiologico, Policlinico Tor Vergata, Roma

Aims: The aim of our study is to evaluate the impact on ST-segment elevation myocardial infarction (STEMI) care during the Coronavirus Virus Disease 2019 (COVID-19) pandemic, through the analysis of cases of patients with STEMI who underwent percutaneous coronary intervention (PCI) at our department.

Methods and results: We performed an observational study on early data collected during social restrictions of Italian Government in our PCI centre with 24/7 on-site interventional cardiologist availability. All consecutive patients affected by STEMI, from March, 9 to May, 4 2020, were collected and compared with STEMI treated during the same period of 2019. During the lockdown, we observed a 55% reduction of STEMI patients admitted to our catheterization laboratory, when compared to the same period of 2019 (26 vs 47 patients). Changes in all time components of STEMI patients admitted in Policlinico A. Gemelli of Rome for STEMI during the Italian lock-down, non-covid patients admitted during the pandemic. The aim of this study is to assess the impact of COVID-19 pandemic on the management and outcomes of patients pre-senting with STEMI during the period of the Italian lockdown.

603 The negative impact of COVID-19 pandemic for non-COVID patients with acute coronary syndromes
Luigi Cappannoli1,2, Daniele Rodolico1, Stefano Migliaro1,3, Filippo Crea1,2, and Domenico Di Mario1
1Università Cattolica del Sacro Cuore, 2Dipartimento di Scienze Cardiologiche e Toraciche, Fondazione Policlinico Agostino Gemelli IRCCS

Aims: Coronavirus disease-2019 (COVID-19) affects cardiovascular patients in various way, both directly, because patients with previous cardiovascular disease face excess risks of severe illness and cardiovascular events, and indirectly, as demonstrated by the decline in the total number of hospitalizations, a decrease of primary percutaneous coronary intervention and a significantly longer median length of stay (LOS) in non-covid patients admitted during the pandemic. The aim of this study is to assess the impact of COVID-19 pandemic on the management and outcomes of patients pre-senting with STEMI during the period of the Italian lockdown.

Methods and results: We conducted a retrospective analysis on non-covid patients admitted in Policlinico A. Gemelli of Rome for STEMI during the Italian lock-down, from March 9th to May 3th 2020, making a comparison with the same period of 2019. We collected data about the delays between the onset of symptoms and the culprit lesion treatment (symptoms onset to first arrival to ED; ED arrival to first diagnosis by EKG; ED arrival to ED discharge; ED discharge to cath-lab arrival; cath-lab arrival to wire crossing; symptoms onset to wire crossing: arrival at PCI centre to wire crossing) and about the inhospital outcomes (MACEs). We reported a mild decrease in the
number of hospitalization due to STE-ACS in 2020 (22) compared with 2019 (26) and a significant increase of in-hospital MACE in 2020 (27.3% vs 3.8%; p = 0.038). No remarkable “patient delay” was observed in 2020 compared to 2019 (311 vs 216 minutes; p = 0.541), but a significant prolongation of the time from patient arrival at PC1 centre to wire crossing (94 vs 196 minutes; p = 0.038) was reported, due to the need to certainly assess the negativity to SARS-CoV2. Interestingly, we did not report differences between 2020 and 2019 in LOS (7.5 vs 9.5 days; p = 0.395).

Conclusion: Implementing STEMI chain of survival with adjunctive measures required by COVID-19 pandemic may negatively impact on the management of patients presenting with acute cardiovascular conditions. Prolongation of total ischaemic time in non-covid patients is not justified and should be avoided, as it does not provide clinical advantage and, conversely, worsen clinical in-hospital (and probably out-hospital) outcomes.

323 Unusual stroke during COVID-19 pandemic
Luca Felice Cerrito1, Martina Milani2, and Antonella Moreo2
1Section of Cardiology, University of Verona, Verona, Italy, 2Cardiovascular Department, Niguarda Great Metropolitan Hospital, Milan, Italy

During Coronavirus Disease 2019 (COVID-19) pandemic there was a dramatic drop of admissions of patients with acute coronary syndrome. There are plenty of theories circulating as to what could possibly drive STEMI rates down during this pandemic: patient’s reluctance to go to a hospital during COVID-19 outbreak, lack of availability of local doctors and overload of emergency systems. A 54-years old man male was admitted to emergency department because of brain stroke-related symptoms. The patient’s sister called the emergency number reporting the brother didn’t answer the phone and he was at least a week that was suffering of stomach-ache. She also reported that the patient refused to go to hospital because was afraid about COVID-19. At health staff arrival the patients showed global aphasia and right hemisindrome; head-neck CT scan revealed ischemic areas in right insular lobe and left parietal lobe. The patient was negative at COVID-19 test. ECG revealed interstitial ST elevation with associated diffuse Q-waves and extreme QRS axis deviation. Transthoracic echocardiography showed lateral and inferolateral akinesia, severely depressed left ventricular function, hematic pericardial effusion and a laceration of the left ventricle. Coronary angiography revealed 70% stenosis of proximal, 80% of medium tract of left descending anterior coronary, 80% of proximal circumflex coronary, occlusion of 1' obtuse marginal artery (culprit lesion) and dominant right coronary artery with no-significative stenosis. The patient, after heart team's discussion, underwent to urgent heart surgery. During surgery hematic pericardial clot was removed and a blood clot with a small bleeding area was found on infero-lateral wall of left ventricle; was also performed a single coronary artery by-pass on left anterior descending coronary. This case shows an important and rare complication of STEMI. Although cases on myocardial wall rupture are widely reported in literature, must be considered that in this case the patient refused to went to hospital because of COVID-19 outbreak. This case may help to consider that during COVID-19 pandemic infection, some patients died because they refused to go to the hospital or seek for medical help. Also this case may suggest that the chance of telemedicine services, if there was a telemedicine service, we consider that this patients could had contact the doctor by phone and be encouraged to go to the hospital earlier.

281 Admission QT interval and hydroxychloroquine treatment in SARS-CoV-2 patients
Cesare De Gregorio1, Luca Zappia1, Giulia Laterra2, Giorgio Firetto1, NunzioAntonio G. Fichera1, Antonio G. Versace3, and Francesco Luzzia1
1Azienda Ospedaliera Universitaria di Messina, UOC di Cardiologia, 2Azienda Ospedaliera Universitaria di Messina, UOC di Medicina Interna

Aims: During the SARS-CoV-2 outbreak, hydroxychloroquine (HCQ) has been suggested as an active antiviral agent, but iatrogenic effects were a warning for its large use in such patients. Early February, in the absence of international guidelines, we used HCQ for treating SARS-CoV-2 patients. The effects of this drug on QTc interval and incident arrhythmias were investigated between February and April 2020.

Methods and results: Among all patients admitted to hospital for confirmed SARS-CoV-2 disease HCQ treatment was established based on clinical needs and the absence of left bundle branch block, G6PD deficiency, congenital long QT, and basal QTc >500ms. HCQ was administered at a daily dose of 400-600 mg in selected patients, and ECG and clinical findings (heart rhythm, heart rate, QT and QT corrected, arrhythmic events) were measured on admission (T0), treatment course (T1) and at the end of drug administration (T2). A total of 76 patients, aged 69.3 ± 15.4 years, were studied. Intestinal pneumonia was found in 84% of cases. On admission, prolonged QTc was detected in 30 frail patients (39%) at T0, who entered the control group together with another 16 patients unsuitable for HCQ. Overall, 30 patients were eligible to receive HCQ for a maximum of 10 days. In some case azithromycin was given in combination. QTc prolongation (>500ms in 4 cases) was seen in 50% of treated patients, but no serious arrhythmic events (except from premature ventricular beats) were encountered during and after the treatment. Fifty percent of HCQ recipients at a daily dose of 400-600 mg showed iatrogenic QTc prolongation, albeit no ventricular arrhythmias were observed. Though HCQ treatment has not been definitely demonstrated to be effective against SARS-CoV-2 infection, its use in our patient series was uneventful.

267 Cardiac point-of-care ultrasound in hospitalized COVID-19 patients: findings and association with outcome
Vincenzo De Marco1,2, Veneda Giladi1, Giulia Guglielmi2,3, Roberta Della Bona1, Stefano Giovannazzi1,2, Fabio Pesceletti1,2, Alberto Valbusa1, Gian Paolo Bezante1,2, Andrea De Maria1,3, Nicolò Piattoni1,2, Diego Ferone1,2, Paolo Pelosi1,2, Matteo Bassetti1,2, and Italo Porti1,2
1Dicatov—Cardiovascular and Vascular Department, San Martino Hospital, IRCCS for Oncology and Neurosciences, Genoa, Italy, 2Department of Internal Medicine and Medical Specialties (Dimi), Clinic of Cardiovascular Diseases, University of Genoa, Genoa, Italy, 3Infectious Diseases Unit San Martino Hospital, IRCCS for Oncology and Neurosciences, Genoa, Italy, 4Department of Health Sciences (Dissal), University of Genoa, Genoa, Italy, 5Anaesthesia and Intensive Care, San Martino Polyclinico Hospital, IRCCS for Oncology and Neurosciences, Genoa, Italy, 6Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy, 7Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, 8Endocrinology Unit, Department of Internal Medicine and Medical Specialties (Dimi) and Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy

Aims: Cardiovascular involvement has been reported in hospitalized COVID-19 patients. Primary outcome was to describe cardiac point-of-care ultrasound (POCUS) findings in a COVID-19 cohort patients. Secondary outcomes were to assess the association between echocardiographic findings and intensity of care expressed by respiratory distress (RD) grade, as well as the length of hospital stay and all-cause in-hospital mortality.

Methods and results: We performed a retrospective, observational cohort study, including all COVID-19 patients admitted to a tertiary Italian University hospital undergoing cardiac POCUS, and stratified according to the degree of RD at examination. Of 138 patients included in our study, 38 (27.5%) had mild RD, 35 (25.4%) had moderate RD, and 65 (47.1%) had severe RD. Most common abnormalities were left ventricular (LV) hypertrophy (38.4%), mild pericardial effusion (35.6%) and right ventricular (RV) dilatation (26.8%) (Figure 1). LV and RV systolic dysfunction were rare (13.0% and 5.1%, respectively) (Figure 1). LV hypertrophy was more frequent in severe RD. No cardiac POCUS parameter was independently associated with in-hospital mortality, whereas RV dilatation was associated with longer hospital stay (Figure 2).

Conclusion: In COVID-19 patients, cardiac POCUS parameters independently associated with need for more intensive or longer care are LV hypertrophy and RV dilatation, respectively. LV and RV dysfunction are uncommon.
Aims: An increase in cardiac troponin (cTn) in coronavirus disease 2019 has been associated with worse prognosis. Nonetheless, data about the significance of cTn in elderly subjects with COVID-19 are lacking.

Methods and results: From a registry of consecutive patients with laboratory-confirmed COVID-19 admitted to a hub hospital in Italy from 26/02 to 03/07/2020, we selected those >60-year-old and with cTn I (cTnI) measured within 3 days from the molecular diagnosis of COVID-19. When available, a second cTnI value within 48 hours was also extracted. The relationship between increased cTnI and all-cause in-hospital mortality was evaluated by a Cox regression model and restricted cubic spline functions with three knots. Of 343 included patients (median age 75.0 (68.0-83.0) years, 34.7% men), 88 (25.7%) had cTnI above the upper-reference limit (0.046 μg/L). Compared with subjects with normal cTnI, they had more comorbidities, more impaired respiratory exchanges and higher inflammatory markers on admission. Furthermore, they died more often (73.9% vs. 37.3%, \( p < 0.001 \)) over 15 (6-25) days of hospitalization (Figure 1). The association of elevated cTnI with mortality was confirmed by the adjusted Cox regression model (HR 1.61, 95%CI: 1.06-2.32, \( p = 0.039 \)) and was linear until 0.3 μg/L, with a subsequent plateau (Figure 2). Of 191 (55.7%) patients with a second cTnI measurement, 49 (25.7%) had an increasing trend, which was not associated with mortality (univariate HR 1.39, 95%CI 0.87-2.22, \( p = 0.265 \)).

Conclusion: In elderly COVID-19 patients, an initial increase in cTnI is common and predicts a higher risk of death. Serial cTnI testing may not confer additional prognostic information.

Figure 1 and 2.
ventricular and intra-ventricular conduction, abnormal Q/ QS wave, ST segment and T wave changes, corrected QT (cQT) interval and tachyarrhythmias. Overall, any ECG abnormality was found in 120 COVID-19 patients (37%) and 101 (43.5%) no-COVID-19 patients (p = 0.13). Atrial fibrillation was present in 62% and 12.1% of patients in COVID-19 and no-COVID-19 group respectively (p < 0.001). QRS duration was similar in the 2 groups (p = 0.62), but there was a higher prevalence of left bundle branch blocks in no-COVID-19 group (1.9% vs. 6%, p = 0.011). The prevalence of premature supraventricular complexes was lower among COVID-19 patients (p = 0.029), whereas the prevalence of premature ventricular complexes was (p = 0.42), prolonged cQT interval (p = 0.43), ST-segment depression >0.5 mm (p = 0.68) or >1 mm (p = 0.13) and T wave inversion (p = 1.00) did not differ between the 2 groups. However, no differences in ECG variables were found between the 2 groups in a comparison of propensity score matched subgroups of 336 patients (168 in each group).During a follow-up of 45±16 days, 51 deceased patients with symptoms suggestive of Sars-CoV-2 infection (history of fever before out-of-hospital cardiac arrest, with cough, dyspnea, or both) and patients with positive results of pharyngeal swabs test to detect SARS-CoV-2 obtained before the event or after death, from February to April 2020, 156 cases of OHCA were identified, as compared with 78 cases of the same period in 2019. Among patients with OHCA, we reported 68 cases of COVID-19. The 44.9% (n : 70) of the population were women. Overall median age was 79,2 years (female: 83,5;years; male: 75,6 years). Demographic characteristics of patients were similar in 2020 and 2019. The median arrival time was 5,3 min longer in 2020 compared with 2019; the incidence of out-of-hospital death was 6,4% higher in 2020 than in 2019 and no one received cardiopulmonary resuscitation from bystanders in 2020. Initial cardiac rhythm was shockable in 6,4% (n : 10) of patients in 2020 compared with 15,4% (n : 12) in the same period of 2019. Conclusion: during COVID-19 pandemic in Piacenza there was an increase in OCHA compared to the pre-COVID era. A total of 68 patients who experienced OHCA were suspected to have or had a diagnosis of Covid-19; these numbers account for 87,2% of the increase in cases of out-of-hospital cardiac arrest observed in Piacenza in 2020. This may be mainly due to an increased number of acute thromboembolic events occurred during COVID pandemic. Anticoagulant therapy should be considered in COVID-19 patients and the evaluation of D-Dimer could guide patient selection for this therapy.
Abstracts

Castel San Giovanni Ausl Placenza, *Emergency Unitopediale Castel San Giovanni Ausl Placenza, †Medical Ward Unit, Ospedale Castel San Giovanni Ausl Placenza

Aims: Effective respiratory support is crucial in the management of COVID-19. The objective of this study was to evaluate the effectiveness of helmet continuous positive airway pressure (CPAP) in reducing mortality and delaying mechanical ventilation.

Methods and results: Demographic and clinical records from patients admitted to Castel San Giovanni Hospital (Placenza, Italy), with a confirmed COVID-19 diagnosis, between the 15th and 30th of March 2020, were analyzed. A total of 200 patients were included in the analysis, 78% were male, median age was 68.5 years, and 121 (61%) had at least 1 comorbidity. Of the 200 patients, 110 (55%) used only oxygen; 90 (45%) underwent CPAP treatment, 16 of whom (18.6%) were not compliant to CPAP (non-compliant group). In the subgroup compliant with CPAP, the need for intubation was slightly lower compared to the non-compliant group (33.3% vs 37.5%).

A total of 32 (16.1%) patients died overall. The lowest mortality was in the CPAP-compliant group (8.3%) as compared to the non-compliant and no CPAP groups (68.8% and 13.4%, respectively). Mortality was higher in smokers (30%) and in obese patients (19.2%). The number of previous comorbidities had an impact on the mortality rate, especially for COPD, hypertension and malignancy.

Conclusion: This retrospective study indicated the effectiveness of helmet CPAP, in hospitalized patients with ARDS secondary to COVID-19, in reducing both mortality and the need for endotracheal intubation.

329 Impact of COVID-19 outbreak on workload and case-mix in a dedicated CMR laboratory

Alessandra Scattelletta1, Carlo Di Nardo1, Raffaella America2, Carmine Emanuele Pascale2, Giuseppe Russo2, Pasquale Guarini2, Giovanni Esposito1, and Santo Delegrottaglie1

1Università Degli Studi di Napoli Federico II, 2Casa di Cura Villa dei Fiori Acerra

Aims: Cardiac magnetic resonance (CMR) is an extremely valuable imaging tool for diagnosis and monitoring of multiple cardiac conditions. During the spring of 2020, the rapid spreading of COVID-19 outbreak in Italy required political and societal responses that significantly affected social life, economy, and healthcare. During the worse phase of the outbreak, the entire national health service has been reshaped in order to manage the incident cases and be prepared to the new potential cases of COVID-19. CMR laboratories throughout the Country either completely stopped their clinical activity, with staff reassigned to other hospital activities, or performed only urgent scans, meaning those possibly impacting on the correct management of serious clinical entities. Aim of this study was to describe the characteristics of scanning activity performed during the period of national lockdown in a dedicated CMR laboratory.

Methods and results: From the general log-book of the CMR laboratory at Clinica Villa dei Fiori Acerra (Naples), operating in an Italian region only mildly involved by the outbreak, data about scanning activity as performed during the lockdown period (March-May 2020) were collected and compared with the level and type of activity in 2019 as a reference. We focused on the total number of exams performed, frequencies of clinical indications as well as modality of patient referral (inpatient vs outpatient). In 2019, the CMR laboratory performed a total of 889 exams, with 45% of inpatients and 55% of outpatients in an outpatient setting (75%) (Figure 1A). The most common clinical indications were cardiomyopathies (37%) and ischaemic heart disease (27%, when including both acute and chronic presentation), followed by congenital heart diseases (13%) (Figure 1B). The relative prevalence of each clinical indication remains substantially unchanged when only the March-May 2019 period was considered. In the corresponding time period of 2019 (March-May), a significant reduction in the total number of performed scans was observed (75%–47%). During the lockdown period in 2020, the inpatients accounted for 71% of the CMR exams (Figure 2A), with the main clinical indications being acute cardiac conditions (44%, when including acute coronary syndrome, myocardial infarction with no coronary obstruction and myocarditis) and advanced heart failure from known or suspected cardiomyopathy (29%) (Figure 2B).

Conclusion: During the most acute phases of COVID-19 outbreak in Italy, CMR scanning activity was significantly impacted both in quantitative and qualitative terms. In agreement with specific SCAR recommendations, mostly urgent and acute clinical conditions led to the execution of a CMR exam during those months. More studies are needed to fully assess the short-term and long-term impact of this pandemic on the patterns of use of advanced cardiovascular imaging and consequences on clinical management of cardiac patients.

108 COVID-19-related arrhythmic storm as early manifestation of the infection: a case report

Filippo Dossi1, Paolo Franca1, Chiara De Toni2, Alessandro Marinì1, Giuseppe Sanna1, Guido Parodi1, and Pier Sergio Saba1

1Cardiologia Clinica ed Interventistica—Azienda Ospedaliera Universitaria di Sassari

Aims: Cardiovascular manifestations of COVID-19 are mainly related to thrombotic complications induced by the viral infection. However, some epidemiological report suggests a role of COVID-19-related electrical instability as a contributor to the disease’s mortality. This electrical vulnerability could be even more evident in patients with previous coronary artery disease, as occurred in the case here reported.

Methods and results: A 63-year-old man was admitted in March 2020 in our hospital for recent pain and ECG manifestation of extensive anterior STEMI and hemodynamic instability. His past medical history was remarkable for arterial hypertension, type-1 diabetes mellitus and dyslipidemia. Immediate coronary angiography was performed, that showed diffuse coronary artery disease of the right coronary artery (chronic total occlusion), the left main trunk, and the origin of anterior descending (LAD) and circumflex arteries. The proximal circumflex artery and obtuse marginal branch were also involved. An emergency percutaneous coronary intervention was performed. After staged PTCA and multiple implantations of drug-eluting stents complete coronary revascularization was achieved. Transthoracic echocardiography, that in the acute phase showed extensive wall motion abnormalities with severe left ventricular systolic dysfunction (EF = 30%), after revascularization gradually improved (EF = 40%). In the following days, the clinical conditions were stable. A routine chest X-ray indicated no pleural effusion or pulmonary congestion. Arterial Blood Gas (ABG), without oxygen support, showed no impairment in gas exchanges; blood tests were also normal apart for blood glucose levels which remained unstable and substantially elevated despite appropriate insulin therapy. During the night of the day 10th after admission, the patient reported dry cough and fever (37.5 °C). No remarkable symptoms were reported in the day after. However, in the morning of the 12th day, the patient suddenly presented with a witnessed cardiac arrest. Cardiopulmonary resuscitation was promptly initiated and ventilar fibrillation (VF) was rapidly identified and treated with 200 Joules DC shock. However, cardiac rhythm rapidly degenerated to new repeated episodes of VF despite appropriate Advanced Cardiovascular Life Support protocol was promptly initiated. ABG showed no electrolytes imbalance. To rule out potential acute-stent-thrombosis as a cause of recurrent VF, an emergency coronary angiography was performed showing the patency of the implanted stents and a TIMI flow grade 3 in all the main coronary branches. The patient was in the same day tested positive for Sars-CoV-2 infection. In the next day, interstitial pneumonia appeared at a chest high-resolution computed tomography. In the following days the patient developed multi-organ failure and after recurrent episodes of VF refractory to therapy eventually died 18 days after initial admission.

Conclusion: This case confirms that electrical instability might severely complicate COVID-19 in the very early phases of the disease. The concomitant presence of previous cardiovascular disease might act as a facilitator for the occurrence of an arrhythmic storm. In the context of COVID-19 pandemic, if the infection is suspected or proved, we suggest that a 24h in ECG monitoring should be considered in patients with established cardiovascular diseases.

522 Acute myocardial infarction in asymptomatic patient in subacute phase of SARS-CoV-2 disease: a case report

Ilaria Ferrari1, Ilaria Cardillo1, Vania Chilanta1, Flavio Giuseppe Biccirè1, Michele Schiari1, Concetta Torroni1, Gaetano Tanzilli1, Carlo Gaudio1, and Francesco Barilà1

1Department of Cardiovascular, Respiratory, Neurhinologic, Anesthesiologic and Geriatric Services—Sapienza, University of Rome, Italy—Umberto I Hospital Rome

Aims: The clinical manifestations of Sars-Cov-2 infection are mostly dominated by respiratory tract symptoms, but the cardiovascular complications increase risk of morbidity and mortality in these patients. Sars-CoV-2-related cardiac involvement is mostly described in patients with cardiovascular risk factors and in the acute phase of viral disease.

Methods and results: A 43-year-old man, who had Sars-CoV2 viral syndrome two months before, without cardiovascular risk factors, was admitted to our emergency department for acute chest pain and shortness of breath. At admission, he still tested positive for Covid-19, despite complete resolution of typical Sars-CoV2 viral syndrome 30 days before. His hemodynamic parameters showed a regular heart rate of 85 beats/minute and blood pressure of 110/80 mmHg. The electrocardiogram showed an anterior ST-elevation myocardial infarction (STEMI). The patient was immediately addressed to cathlab for primary percutaneous coronary intervention (pPCI). The invasive coronary angiogram revealed a proximal occlusion of left descending coronary artery, with other coronary vessels free of atherosclerotic disease. The patient was in the same day tested positive for Sars-CoV-2 infection. In the next day, interstitial pneumonia appeared at a chest high-resolution computed tomography. In the following days the patient developed multi-organ failure and after recurrent episodes of VF refractory to therapy eventually died 18 days after initial admission.

Conclusion: This case confirms that electrical instability might severely complicate COVID-19 in the very early phases of the disease. The concomitant presence of previous cardiovascular disease might act as a facilitator for the occurrence of a thrombotic event. In the context of COVID-19 pandemic, if the infection is suspected or proved, we suggest that a 24h in ECG monitoring should be considered in patients with established cardiovascular diseases.
function with an ejection fraction of 45% with hypokinesia of apex and mid-distal anterior wall. In-hospital permanence was free of any complication and the patient was eventually discharged after 7 days, with negative naso/oropharyngeal swab for Sars-CoV2.

Conclusion: Acute Coronary Syndrome is a possible late complication of pauciymnomatic Sars-CoV2 disease. Immediate diagnosis of myocardial infarction is crucial in suspected COVID-19 patients, even in patients without classic cardiovascular risk factors. Monitoring these patients in the late asymptomatic phase of the infection may be useful to detect early signs or symptoms of any cardiovascular complications. A longer-term antithrombotic treatment also in patient without critical symptoms of COVID-19 may be suggested to prevent thrombotic complications.

557 Atrial fibrillation in COVID-19: an association with in-hospital mortality

Carlo Fumagalli1, Tommaso Bencini1, Rossella Marcucci1, Federico Lavorini1, liacopo Oliverio1, Andrea Unger1, Niccolò Marchiomin1, and Stefano Fumagalli1

Dipartimento di Medicina Sperimentale e Clinica, Università Degli Studi di Firenze e Azi Careggi, Firenze

Aims: Pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and its related disease (COVID-19) emerged in Wuhan City, Hubei Province, China in December 2019. Among the most vulnerable and frail, those with a history of coronary artery disease (CAD), hypertension, heart failure, history of stroke/TIA. In this study we focused specifically on those presenting with atrial fibrillation (AF) as primary comorbidity, since AF and COVID-19 share some critical risk factors.

Methods and results: We prospectively collected data from patients admitted to Careggi University Hospital, Florence, from March 3rd to July 18th with COVID-19 diagnosis. Variables assessed on hospital admission included: demographics, number of drugs prescribed, cardiovascular (CV) risk factors. Arterial blood gases, laboratory findings and chest-x-ray were collected as well. AF was defined according to current guidelines. Aim of the study was to compare patients' characteristics by presence or absence of AF , to assess the association of AF with survival status (mortality vs. discharge). In addition, patients with an history of AF shown higher CV-risk profile, with significant higher prevalence of hypertension (74.2% vs. 5.1%, p < 0.001), heart failure (46.8% vs. 16.4%, p < 0.001) and of stroke/TIA (22.6% vs. 8.2%, p < 0.001). Patients with AF presented with a cancer history more frequently and had a higher prevalence of cognitive decline (36.1% vs. 15.7%, p < 0.001).

Among laboratory findings, patients with AF had lower levels of lymphocytes, higher creatinine levels (1.5 vs 1.1 mg/dL, p < 0.001), LDH (430.3 vs. 325.8 IU/L, p < 0.001), C-Reactive Protein (CRP, 113.4 vs 83 mg/L) and aPTT. The most important differences between the two populations were reported in the destination at discharge and in-hospital mortality. Mortality rate was higher in AF patients (36.1 vs 14.1%, p < 0.001). AF patients were discharged towards a rehabilitation facility more frequently (16.4 vs 11.3%, p < 0.05).

Baseline independent predictors of AF were age (OR: 1.04 95% CI 1.01-1.08, p < 0.008), number of comorbidities (OR: 1.41 95% CI 1.21-1.64, p < 0.001), CRP (OR: 1.05 95% CI 1.00-1.10, p = 0.025) and aPTT (OR: 1.11 95% CI 1.04-1.18, p < 0.002).

Conclusion: AF is common in COVID-19 patients and is associated with worse outcome. Given the similar risk factors between AF and COVID-19, AF should be regarded as a synergistic and precipitating factor which should warrant prompt and specific care.

322 Giant right ventricular thrombus and COVID-19: a bad luck case?

Ailia Giubertoni1, Alessia Veia1, Luigi Mario Castello1, Simona De Vecchi1, Matteo Santagostino1, Tiziana Cena1, Marco Mennuni1, Giovanni Casali1, and Giuseppe Patti1

AOU Maggiore Della Carità—Novara

We describe a case of a 49-year-old woman hospitalized for COVID-19-related bilateral interstitial pneumonia with severe adult respiratory distress syndrome. Chest CT scan performed in emergency department showed a large mass in the right ventricle, bilateral peripheral pulmonary embolism and extensive ground-glass opacifications involving both lungs (Fig. 1). The patient was admitted to our sub-intensive care unit and treatment with lopinavir/ritonavir, hydroxychloroquine and continuous positive airway pressure was immediately started. Trans-thoracic echocardiography confirmed a floating mass in the right ventricle, which diameters were about 27 x 12 mm (Fig. 2). RV size and function were normal and systolic pulmonary arterial pressure was 60 mmHg.

Surgery was contraindicated because of pneumonia and unfractinated heparin infusion was started. The following day we performed a cardiac magnetic resonance that confirmed the presence of a mass consistent with thrombosis. Since the patient was hemodynamically stable but became intolerant to the continuous intravenous infusion, we switched UH to dabigatran 150 mg bid. Echocardiography performed at 15 days (4 days after starting dabigatran) showed complete thrombus resolution. Ex adiuvantibus diagnosis of RV thrombosis was performed after thrombus resolution. In conclusion, although thrombotic complications have been reported in COVID-19 patients, this case represents the first report of intracardiac COVID-19-related thrombosis. After 4 weeks of hospitalization, the patient was discharged at home in good general condition; no oxygen supplementation was needed and a 6-month treatment with dabigatran was prescribed.

Figure 1 and 2.

251 A rare and silent case of disseminated intravascular coagulation in COVID-19 severe pneumonia

Valeria Grittì1, Simona Pierinni1, Anna Piggi1, Rossella Luciano1, Margherita Pirondini1, and Maurizio Ormagni1

Ospedale Bassini

A 67yo man admitted for COVID-19 bilateral pneumonia rapidly evolved in ARDS requiring CRAP support. He received antiretroviral therapy, hydroxychloroquine, dexamethasone, two tocilizumab doses in addition to LWMH 75UI/kg/die. On 10th day D-Dimer raised (105000 µg/l, ULN 500), right axillary venous thrombosis was detected, no right ventricle impairment was observed at echocardiography; dose of LWMH was doubled. Respiratory conditions were then getting better and CRAP support stopped. On 20th day of hospitalization patient presented acute lower abdominal pain with hypotension and sudden 3 gr/dl hemoglobin loss. CT scan showed a voluminous psa hematoma with active bleeding and bilateral pulmonary embolism (figure below). He underwent trans-catheter embolization of three lumbar arteries with angiographic success, no further blood loss site identified. Few hours later he evolved into multi organ failure shock. Laboratory testing shown hemoglobin loss despite ongoing blood transfusion, normal platelet count, D-dimer 6500 µg/l with a trend toward reduction, mild fibrinogen reduction (115 mg/dl), mild INR raise (1,9 from a range 1,2-1,7) and reduction in anti-thrombin (AT) III activity (45%), confirming disseminated intra-vascular coagulation diagnosis. Hemorrhagic shock support therapy was provided, including fresh frozen plasma and blood transfusions but patient died two days later.

CT scan images left: pulmonary bilateral embolism. Right: psa hematoma.

In novel COVID-19 infection, coagulation disorder set off by inflammation are frequent and abnormal coagulation parameters are associated with poor prognosis. In these patients, DIC incidence seems to be 71,4% among deaths; haemorrhagic events are considered rare. To properly detect coagulopathy during sepsis the International Society of Thrombosis and Hemostasis (ISTH) guidelines recommends Septis-Induced-Coagulopathy (SIC) score considering: PT/INR, platelets count and presence of organ failure. In recent interim guidelines targeted to recognition and treatment of coagulopathy In COVID-19 patients, ISTH recommend to dose and monitoring: D-Dimer, PT, fibrinogen and platelet count, despite these last are often normal. SIC score performed during hospital stay for our patients was not significant (2 points: INR and respiratory impairment), daily measurements of platelets were not alarming. INR was slightly constantly altered as often seen in COVID-19 severe infection and D-Dimer was in reduction after doubling LWWH dose for axillary thrombus. Despite these findings we observed a rare DIC with both thrombotic and hemorrhagic important manifestation, thus giving less diagnostic significance to proposed scores in COVID-19 patients.
Major clinical manifestations then occurred, not responsive to conventional treatment.

545 CE-I and ARBs do not influence the clinical and chest CT presentation of patients with COVID-19 at the onset of disease: Italian multicenter registry
Massimo Mancone1, Fabio Infusino1, Sara Cimirò1, Lucia Ilaria Bortol1, Fabrizio DiOncerzio1, Mariachiara ColaIcisma2, Chiara Andreöli3, Giovanni Battista Forleo4, Marco Schiavone4, Alessandro Depaoli4, Chiara Valentina Lario4, Giuseppina Cecarelli5, Elisabetta DEtore1, Paolo Severino1, Viviana Maiarstili1, Francesco Pugliese1, Gioacchino Galardo1, Grazia Loiudice1, Maria Tecla Pecci1, Massimo Mancone6, Giuseppe Mercuro7, Saverio Muscoli8, Savina Nodari9, Roberto Pedretelli10, Francesco Romeo11, Gianfranco Sinagra12, and Ciro Indolfi13

1Dipartment of Cardiology and Cardiometabolic Unit of Research “Umberto I” Hospital, Nocera Inferiore (Salerno), Italy, 2Department of Cardiology University of Campania Luigi Vanvitelli, Monaldi Hospital, Naples, Italy, 3Division of Cardiology M. Scarlato Covid Hospital, Scafati (Salerno), Italy, 4Division of Cardiology Cardarelli Hospital Naples, Italy, 5Department of Sports Medicine, University of Naples Federico II, Naples, Italy

Aims: In recent months every effort has been made to understand the possible interference of ACE-I or ARBs with ACE-2 receptor and SARS-CoV-2 pathway. Observational studies have shown no clinical impact of home therapy with ACE-I or ARBs on COVID-19, however these drugs are often discontinued upon hospitalization or diagnosis, to evaluate the influence of home therapy with RAAS inhibitors on the chest CT severity score and clinical presentation within 24 hours of diagnosis of SARS-CoV-2 infection, before stopping medications or starting specific therapy for COVID-19.

Methods and results: This is a multicenter, retrospective observational study. All admitted patients diagnosed with SARS-CoV-2 infection who performed chest CT within 24 hours of arrival were consecutively enrolled from March 1 to June 1, 2020. A severity score was attributed to Chest CT by two radiologists in blind to the patient’s clinical information and, as validated by Ran Yang et al., a cut-off of 19.5 was considered to define severe radiological pneumonia. We included 110 patients and 156 were on home therapy with ACE-I/ARBs. In the ACE-I/ARBs group 95% of patients were hypertensive and there was a higher prevalence of diabetes mellitus (ACE-I/ARBs: 26.3% vs non-ACE-I/ARBs 11.3%; p < 0.01). Univariate and multivariate analysis showed that home therapy with ACE-I, ARBs or ACE-I/ARBs were not associated with the risk of CT severity score > 19.5. Factors associated with CT score > 19.5 were male sex (HR—95% CI—p = 0.16), older age (HR—95% CI—p = 0.02), and presence of dyspnea and worse PT ratio on arrival were also associated with more severe radiological pneumonia. Furthermore, therapy with ACE-I, ARBs, ACE-I/ARBs was not associated with the risk of a more severe clinical presentation on arrival in terms of fever, dyspnea, P/F ratio or intestinal symptoms. Finally, the same was true for the outcome of COVID-19 in terms of death, intubation or non-invasive ventilation. The results were consistent in the subgroup with hypertension.

Conclusion: ACE-I and ARBs do not influence the clinical and chest CT presentation of patients with COVID-19 at the time of diagnosis, before discontinuation of therapy or hospitalization.

349 Right ventricular function and pulmonary pressures as independent predictors of survival in patients with COVID-19 pneumonia
Franco Iodice1, Antonello DiDore1,2, Raffaella Scarafà1,2, Lucia Riegler1,2, Biagio Liccardo1, Fabio CresciMRone1, Rosangela Cocchia1, Eduardo Bosso1, and Alessandro Serio2
1Department of Cardiology and Intensive Coronary Unit “Umberto I” Hospital, Nocera Inferiore (Salerno), Italy, 2Department of Cardiology University of Campania Luigi Vanvitelli, Monaldi Hospital, Naples, Italy

Aims: We sought to determine the possible association of right ventricular (RV) function and pulmonary pressures with mortality in patients with COVID-19 pneumonia.

Methods and results: We studied 115 consecutive patients (64.6 mean age, range 20-88 years; 40% female) with positive SARS-CoV-2 laboratory test results and TC-conformed interstitial pneumonia. We defined cardiac injury as high sensitivity Troponin I (hs-TnI • ECLIA method) blood levels above the 99th-percentile upper reference limit. RV end-diastolic basal and mid tracts diameters, tricuspid annular plane systolic excursion (TAPSE), pulmonary artery systolic pressure (PASP), mean pulmonary artery pressure (mPAP), tricuspid inflow E/A ratio and tricuspid regurgitation peak velocity (TRV) were assessed. A total of 26 out of 115 patients had cardiac injury (mean age 73.5), had more frequently systemic hypertension (61.5% vs 22.9%; P < 0.001), higher levels of C-reactive protein (mean 98.8 [45.8-130.4] vs 38.9 [22.9-26.3] mg L-1; P < 0.001) and of D-dimer (mean 4.8 [3.2-7.1] vs 2.1 [0.5-3.4] mg L-1; P < 0.001); multiple ground-glass opacities in CT-findings (69.2%/33.7%) and multiple consolidations by lung ultrasound (76.6/38.2%) were found. U-diameters and ejection fraction (EF) were comparable between the two groups. Conversely, RV end-diastolic basal tract (35.8 ± 4.2 vs 31.2 ± 2.6; P < 0.01) and mid tract (32.4 ± 3.9 vs 28.6 ± 3.7; P < 0.01), TRV (3.4 ± 0.6 vs 2.9 ± 0.5; P < 0.001) and mPAP (29.6 ± 2.9 vs 23.6 ± 2.7; P < 0.01) were significantly increased in patients with cardiac injury, while tricuspid inflow E/A ratio (0.77 ± 0.5 vs 1.1 ± 0.6; P < 0.01) and TAPSE (15.4 ± 3.2 vs 20.3 ± 4.7; P < 0.001) were reduced. Patients with cardiac injury had a higher mortality than those without cardiac injury (50% vs 7.8%; P < 0.001).

Conclusion: Increase of mPAP and RV dysfunction are associated with higher risk of in-hospital mortality in patients with COVID-19 pneumonia and cardiac injury.

156 Atrial fibrillation in a patient presenting with coronavirus disease-2019 (COVID-19) infection
Norman Namaida1, Giorgio Torella1, and Antonino Cerciello2
1Clinica Trusso—Ost彼此ani—Napoli

SARS-CoV-2 is a novel virus that has spread rapidly throughout the world causing a potentially life-threatening disease, COVID-19, causing disproportionately high mortality among elderly patients with concomitant urban and coronary cardiovascular diseases. The clinical cardiovascular manifestations of COVID-19 include elevation of cardiac biomarkers (ischaemic or non-ischaemic aetiology), cardiac arrhythmia, arterial and venous thromboembolism (VTE), and cardiogenic shock and arrest. Multiple mechanisms have been proposed to explain influenza triggering arrhythmias, among them severe systemic, arterial, and myocardial inflammatory reaction seems to be one of the most plausible. In patients with underlying ischaemic cardiomyopathy, the worsening of ischemia by increased oxygen demand and potential acute coronary syndromes led by influenza can also have a role in the increase of arrhythmic events. Furthermore, the systemic inflammatory response would make anticoagulation therapy for atrial fibrillation very complex. Arrhythmia could be the first presentation of COVID-19, and new-onset and/or progressive arrhythmia could indicate cardiac involvement.

We describe a case of a male presenting with COVID-19 infection who experienced atrial fibrillation (AF) which resolved with rate and rhythm control strategies, and supportive care. Case Report: A 80-year-old male with …presented to the emergency room with a symptom of fever, shortness of breath and cough over the preceding 4 days. His Vital signs indicated heart rate of 160 beats/minute blood pressures of 160/90 mmHg, respiratory rate of 32 breaths per minute with an oxygen saturation of 86% on room air. A 12-lead electrocardiogram revealed atrial fibrillation and rate-related ST-T segment changes. A chest radiograph did not reveal any acute cardiopulmonary disease. Diagnostic laboratory investigations revealed a high d-dimer 500 mg/dl and pro-BNP: 600 pg/ml, while cardiac biomarkers were normal. In this room he was initiated on a amiodarone an 1 digoxin bolus. In the interim, the patient’s COVID-19 test was positive. He reverted to normal sinus rhythm within 48 hours. This patient revealed several electrolyte abnormalities, including hypokalemia, hypomagnesemia, all of which were aggressively repleted.

Further observational studies are required to characterize the nature and classification of arrhythmias in this COVID-19 pandemic.

614 Effects of COVID-19 on cardiovascular fellowship in Italy
Isabella Leo1, Antonio Strangi2, Carmen Anna Maria Spaccarotella3, Francesco Barillà4, Cristina Basso5, Maria Pia Calabò6, Antonio Curci7, Pasquale Perrone Filardi8, Massimo Mancone9, Giuseppe Ferri10, Saverio Muscoli11, Savina Nodari12, Roberto Pedretelli13, Francesco Romeo14, Gianfranco Sinagra15, and Ciro Indolfi16
1Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia, University, Catanzaro, Italy, 2Department of Clinical, Internal, Anesthesiological, and Cardiological Sciences, University of Rome Tor Vergata, Rome, Italy, 3Cardiovascular Pathology Unit, University of Padua, Padua, Italy, 4Department of Human Pathology, University of Messina, Messina, Italy, 5Department of Advanced Biomedical Sciences Federico II University, 6Sapienza University of Rome, Rome, Italy, 7Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, 8Department of Medicine, Tor Vergata University of Rome, Rome, Italy, 9Cardiovascular Department, University of Trieste, Trieste, Italy

Aims: Italy has been the first European Country to be hit hard by the COVID-19 pandemic. It is probable that, in the midst of the emergency, the impact that the pandemic could have had on the training of cardiovascular fellows in training (FTTs) has been overlooked. To investigate the perception of cardiovascular FTTs about the effects of COVID-19 pandemic on cardiovascular education in Italy.

Methods and results: a 23-item survey has been created on Google form and subsequently sent to 1443 Italian cardiovascular Fellows in Training (FTTs) registered on the database of the Italian Society of Cardiology (ISC). The participation was completely voluntary and the system has been set to avoid double entries. 633 FTTs: 44% of the Italian FTTs in cardiology completed the survey. 24.5% of respondents have been employed in COVID-19 units and 95% affirmed that the cardiological training program (clinical activities, didactics or both) has been somewhat changed during the pandemic (Fig 1a). For 61% of the FTTs the COVID-19 had a negative effect on their education (Fig 1b). Moreover, 59% of the respondents believe that they would not be able to completely fill the gap gained during that period over the rest of their training. The top five penalized aspects of cardiological education were frontal.
teaching, participation to scientific conferences, training in advanced echocardiography, circulation within the training network and the acquisition of skills on outpatient clinic care. Preferred activities during the lockdown were studying, working on research projects and learning about SARS-CoV-2 infection. Finally, a negative impact on psycho-physical well-being has been reported by 86% of the trainees. In this study, we determined the pattern of high sensitivity troponin elevation in patients affected by SARS-CoV-2 and the prevalence of myocardial injury in this population; furthermore, we investigated the predictive value of hs-Tn on disease severity and mortality.

Methods and results: This retrospective single-centre study analyzed all 758 patients in whom hs-TnI was determined in our hospital from 20 February 2020 to 09 April 2020. One hundred-eighty nine of these patients received SARS-CoV-2 diagnosis. Demographic data, laboratory findings, comorbidities, and treatments were collected and analyzed in patients with COVID 19. A total of 189 hospitalized patients with COVID-19 were included in the final analysis. The median age was 66 years old (SD 12) and 61 (32.35) were female. During the stay, a total of 28 patients (14.8%) needed admission in Intensive Care Unit and 32 patients (13.7%) died. The prevalence of myocardial injury in our COVID-19 population is of 16% (31 subjects out of 189). The patients with cardiac injury were older, and had a greater number of cardiovascular comorbidities, in particular history of hypertension and ischaemic heart disease; in addition, they had higher values of acute phase and inflammatory markers and leucocytes. The patients with hs-TnI above the 99th percentile cut-off required more frequently hospitalization in ICU (10 [22.3%] vs 8 [11.4%]; P = .020) and the mortality rate was significantly higher (17 [54.8%] vs. 15 [9.5%]; p < .001). A multiple regression analysis was carried out to investigate whether hs-TnI could significantly predict the degree of COVID-19 disease: hs-TnI and CRP contributed significantly to the model (B = 0.525, p < .001; B = 0.001, p = .020, respectively). In addition, we included 189 patients with complete data for all variables (32 non-survivors and 151 survivors) in the multivariable logistic regression model. We found that hs-TnI at admission, older age and CRP levels were associated with increased odds of death.

Conclusion: Myocardial injury is prevalent in patients affected by SARS-CoV-2 and the patients with hs-Tn value above the upper reference limit are older and had a greater number of cardiovascular comorbidities. In this study we demonstrate a high positive predictive value of hs-Tn for disease severity and in-hospital death. Therefore, it may be reasonable to use high sensitivity troponin as a screening tool in post-recovery COVID-19 patients.

Methods and results: In this pilot study, we enrolled subjects with a confirmed diagnosis of COVID-19 after hospital discharge at home. A wearable device used (L.I.F.E.) (a technologically advanced T-Shirt device composed of ink-based dry electrodes linked to standard 12-lead ECG monitoring, 5 respiratory strain sensors, 1 accelerometer, a digital pulse oximeter) was used. Monitoring was carried out for at least 7 days and comprehended a two-hour monitoring period a day during rest and a short exercise (6 minutes of brisk walking) and an overnight sleep monitoring on the last day. Seventeen COVID-19 patients (male 8; age 54.4 ± 15.3 year old; BMI 25.1 ± 3.1) were enrolled at hospital discharge. They underwent 12.5 ± 2.5 (7-17) days of monitoring. Clinical characteristics of the population and data monitoring are shown in Table 1. Twelve patients (70.6%) performed the nighttime monitoring. Among them, one showed an apnea-hypopnea index (AHI) of 20, suggestive of moderate sleep apnea syndrome.

Conclusion: Our study demonstrated that a post-discharge home monitoring program for COVID-19 patients is feasible and safe. The L.I.F.E. T-Shirt device was able to collect a full set of cardiorespiratory parameters (i.e. heart rate, a full ECG, respiratory rate, SpO2), both at rest and during a brief exercise. Finally, we were able to identify only one patient without any previous disease who presented post-COVID sleep apnea syndrome. Further studies are certainly needed to assess the prevalence and the clinical impact of this complication in post-COVID-19 patients.
397 “You can leave your mask on”: effects on cardiopulmonary parameters of different airway protection masks

Fabiana De Martino1, Massimo Mapelli1,2, Elisabetta Salvioni1, Irene Mattavelli1, Paola Gagliandolo1, Carlo Vignati1, Stefania Farina1, Pietro Palermo1, Riccardo Marangà1,2, Gerardo Lo Russo1,2, Alice Bonomi1, and Piergiuseppe Agostoni1,2
1Centro Cardiologico Monzino, 2Universita Degli Studi di Milano

Aims: In December 2019, in the city of Wuhan (China), a potential new causative agent of pneumonia, called the new coronavirus 2019 (nCoV-2019) was identified. Since then, the need to contain the global spread of the infection has become urgent through specific social distancing procedures and through the use of individual protection devices (i.e. airway protection masks). In the media doubts were raised about the impact of different types of masks on daily physical activity, in particular for those who perform physical exercise. In this context, we aimed to evaluate cardiopulmonary parameters, assessable through a cardiopulmonary exercise test (CPET), to highlight any differences with the use of surgical mask or filtering facepiece particles class 2 (FFP2) mask compared to the test performed under normal conditions.

Methods and results: 12 healthy subjects, enrolled in July 2020, performed three consecutive CPETs at least 24 hours apart, but within 2 weeks, without wearing airway protection mask, with surgical mask and with FFP2 mask. The execution order of the CPETs was assigned in order to cover all possible combinations. During the CPETs, the consumption of Watts reached will be obscured to the subject. Before the start and immediately after the end of each CPET, Maximum Inspiratory Pressure (MIP) and the Maximum Expiratory Pressure (MEP) was also assessed. Comparing the three conditions, we observed a progressive significant reduction in oxygen Intake, carbon dioxide output, ventilation and respiratory rate at rest as well as at peak exercise (table 1). The workload also decreased. We did not notice differences in blood oxygen saturation nor adverse events such as arrhythmias or ischaemic events. MIP/MEP comparison did not reveal significant respiratory muscles fatigue.

Conclusion: The use of airway protection masks during pandemics (e.g. nCoV-2019) is a key safeguard to contain viral transmission. In healthy subjects it reduces, both at rest and during exercise, ventilation values (mainly due to reduction of respiratory rate) without detectable alteration of arterial saturation, heart rate, respiratory muscle fatigue and/or adverse events even during a maximum effort. Our speculative hypoth-thesis is that the effect is likely to be related to the presence of a mechanical obstacle to ventilation. Our data show that the use of masks is still compatible with the execution of physical activity even if the maximum workload is slightly reduced. In conclusion airway protection masks (both surgical mask and FFP2) can be safely used in daily life despite a slight impact on ventilation and metabolic parameters.

574 Telemedicine and remote home monitoring in COVID-19 era: a valuable surveillance tool for patients with cardiac devices

Andrea Matteucci1, Michela Bonanni1, Marco Centinii1, Domenico Sergi2, Gianluca Massaro3, Federico Zanin3, Valeria Cammalleri3, Giuseppe Stifano1, and Francesco Romeo3
1UOC Cardiologia Policlinico tor Vergata Roma

Aims: In-hospital management of patients with cardiac implantable electronic device (CIED) has been considered a critical challenge since the early stages of COVID-19 outbreak. In order to safeguard public health, routine in-hospital controls of CIEDs were converted into remote home monitoring (HM). The aim of our study is to investigate the impact of lockdown period on CIEDs patients and its influence on in hospital admissions through the analysis of HM data.

Methods and results: We analysed data recorded from 312 patients by HM during the national state of emergency related to COVID-19 and then we compared data from the same period of 2019. Emphasis has been given to heart failure alarms and arrhythmia alarms. We observed a significant reduction of remote monitoring events in 2020, when compared to 2019. Non-sustained ventricular tachycardia episodes decreased (18.3 VS 9.9% p = 0.002) as well as those for atrial fibrillation (29.2% VS 22.4% p = 0.019). In contrast, heart failure alarm activation was lower in 2019 than in 2020 (17% VS 25.3% p = 0.012). Nevertheless, hospital admissions for critical events recorded with CIEDs dropped in 2020, including those for heart failure.

Conclusion: HM has ensured the surveillance of patients with cardiac devices even when outpatient visits were not possible. Arrhythmic events decreased significantly compared to those observed in 2019. Similarly, hospital admissions have also decreased dramatically, including those for heart failure, despite the increased exacerbations of heart failure shown by HM.

505 Impact of coronavirus pandemic in the management of patients with severe cardiovascular disease: the experience of a cardiology outpatient clinic in Lombardy region

Francesco Fioretti1, Giuliana Cimino1, Antonio Milionid1, Angelica Cersosimo1, Andrea Aquila3, Mariangela Piazzani1, Alberto Madurera1, Laura Lupi1, and Savina Nodari2
1University of Brescia, Italy, 2ASST Spedali Civili Hospital and University of Brescia, Italy, 3ASST Spedali Civili Hospital of Brescia, Italy

Aims: During the lockdown period in Italy, from March 11th to May 4th 2020, a progressive increase in COVID-19 cases occurred in the Lombardy Region. The current rise in COVID-19 cases has led to an increasing involvement of hospitals, in order to face the Coronavirus outbreak, shifting health-care resources towards the management of COVID-19 patients. This has led, on the other hand, to a progressive decrease in hospital admissions due to conditions not associated with SARS-CoV2 infection. At the same time, the regional governments have provided for the suspension of all outpatient activities, with the exception of the non-deferrable one. It was decided to postpone any elective intervention, referring to COVID free hospitals any urgent or emergency intervention. We aimed to verify the impact of Coronavirus outbreak in the management of patients with high risk of morbidity and mortality, followed at the Cardiology Outpatient Clinic of our hospital, that was a Hub centre for COVID patients.

Methods and results: We compared the total number of Day Hospital (DH) visits for worsening heart failure (WHF), severe aortic stenosis waiting for Transcatheter Aortic Valve Implantation (TAVI) and atrial fibrillation (AF) requiring electrical cardioversion (ECV) between March 4th and May 4th of 2019 with those that refer to the same period in 2020. Then, we evaluated the same data in the 30 days following the end of the lockdown (May-June 2020). As reported in Table 1, the number of DH visits during March-May 2019 was approximately double compared to the ones in the same interval time in 2020 (81 vs 34 patients). Instead, in just one month (18/05-18/06/2020) there was a significant increase in the number of accesses for WHF (globally 22), if compared with those (21 in total) during the entire lockdown (lasting three months, from 04/03 to 04/05/2020).

Conclusion: These data confirm how the COVID outbreak impacted negatively on the appropriate management and timing of therapeutic intervention for severe cardio-vascular disease, in particular those with high risk of events and mortality, especially in the regions with highest number of hospitalizations and deaths for SARS-CoV2.

393 Arrhythmic burden in COVID19 patients outside the ICU—experience of a third-level center

Giovanni Pereto1, Simone Sala1, Alberto Zangrillo1, Simone Gulletta1, and Paolo Della Bella1
1IRCCS San Raffaele Hospital And University, Milan, Italy

Aims: No studies investigated the prevalence of arrhythmias among clinically-stable patients affected by COVID-19.
Methods and results: We assessed prevalence, type, and burden of arrhythmias, by a single-day snapshot in seven non-intensive COVID Units at a third-level centre. We enrolled 132 inhospital patients (mean age 66 ± 14y; 66% males) diagnosed with COVID-19 infection. Arrhythmic episodes were detected in 12 patients (9%). In detail, 8 had atrial fibrillation, 1 ventricular tachycardia, and 3 paroxysmal supraventricular tachycardias. There were no cases of ventricular arrhythmias or new-onset atrioventricular blocks. In addition, we report no patients with QTc interval > 450 ms. Conclusion: Our single-day snapshot survey suggests that the prevalence of arrhythmias among clinically stable COVID-19 patients is low. In particular, no life-threatening arrhythmic events occurred.

284 Segmental and global longitudinal strain differences between children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 pandemic and Kawasaki disease: preliminary data from an ongoing study

Enrico Pizzicelli1, Alain Fraisse4, Heechan Kang1, Carles Bautista-Rodriguez1, and Giovanni Di Salvo1
Royal Brompton Hospital

Aims: The paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) and Kawasaki disease (KD) have overlapping features. This study aimed to describe strain segmental analysis among both entities.

Methods and results: Retrospective review of strain segmental analysis within 4 weeks of presentation of symptoms among children diagnosed with PIMS-TS between April and June 2020 and a historic cohort of typical KD from the Royal Brompton Hospital, London. We included 33 PIMS-TS patients (23 males, 69.7%) at a mean age of 5.8 ± 4.5 years old and 45 KD patients (31 males, 68.6%) at a mean age of 8 ± 4.9 years old. Left ventricle ejection fraction (LVEF) was normal in both groups (63.3% ± 63.5%; p = 0.89), 4/33 PIMS-TS children (12.1%) had coronary arteries abnormalities (CAA), whereas 100% of KD cohort had CAA. Both groups had a normal global longitudinal strain (GLS), but in KD it was significantly reduced compared to the PIMS-TS group (-20% vs -22%; p = 0.008). Basal segments were the most affected in KD with significant difference in the basal anterolateral and anterosternal strain compared to PIMS-TS (respectively -18.2% vs -23.4%; p = 0.001 and -16.7% vs -22.7%; p = 0.001). KD had a greater anterior, anterolateral and posterior segments involvement with a significant reduction in the anterolateral mid-wall longitudinal strain (-18.3% vs -22%; p = 0.002). Apical segments were less involved, with significant difference only in the septal and inferior apical strain (respectively p = 0.001 and p = 0.032).

Conclusion: These preliminary data showed that after 4 weeks from the onset of symptoms, all PIMS-TS patients had a normal LVEF and GLS and different segmental involvement compared to KD cohort. We hypothesize that these findings may be related to direct myocardial damage in PIMS-TS rather than caused by coronary perfusion abnormalities.

584 The value of ECG changes in risk stratification of COVID-19 patients

Luca Bergamaschi1, Matteo Armillotta1, Emanuela Concetta DiAngelis1, Pasquale Paololo1, Sebastiano Toniolo1, Michele Fabrizio1, Francesco Angelii2, Francesco Donati1, Ilenia Magnani1, Andrea Rinaldi1, Chiara Chiti1, Andrea Stefanizzii1, Mauro Biffi1, Carmine Pizzi1, and Nazzareno Galie1

Aims: To assess the predictive value of electrocardiograms in COVID-19 patients.

Methods and results: We evaluated 269 consecutive patients admitted to our Centre, with confirmed SARS-CoV-2 infection. ECGs available at admission and after one week from hospitalization were assessed. We evaluated the correlation between ECGs findings and major adverse events (MAE) as the composite of intra-hospital all-cause mortality or need for invasive mechanical ventilation. Abnormal ECGs findings and major adverse events (MAE) as the composite of intra-hospital all-cause mortality or need for invasive mechanical ventilation. Abnormal ECGs findings and major adverse events (MAE) as the composite of intra-hospital all-cause mortality or need for invasive mechanical ventilation. Abnormal ECG findings and MAE were more common in patients who developed MAE (p = 0.04) and p = 0.02, respectively). Concerning ECGs recorded after 7 days (159), abnormal findings were reported in 53.5% of patients and they were significantly more frequent in those with MAE, as shown in Figure 1. Among abnormal ECGs, ischaemic alterations and left ventricular hypertrophy were significantly associated with a higher rate of MAE. The multivariable analysis showed that the presence of abnormal ECG at 7 days of hospitalization was an independent predictor of MAE (HR 3.2; 95% CI 1.2-8.7; p = 0.02). Furthermore, patients with abnormal ECG at 7 days more often required transfer to intensive care unit (p = 0.01) or renal replacement therapy (p = 0.04).

Conclusion: Patients with COVID-19 should receive ECG at admission but also during their hospital stay. Indeed, electrocardiographic alterations during hospitalization are associated with MAE and infection severity.

Figure 1 Kaplan–Meier Curves for Primary Outcome of MAE.

525 Endothelial dysfunction in COVID-19 patients assessed with endo-Pat2000

Giuliana Cimino1, Emiliano Calvi1, Edoardo Pancaldi1, Greta Pascarello1, Nicola Bernardi1, Riccardo Maria Inclaini1, Enrico Vizzardi1, Riccardo Raddino1, and Marco Metra1

Aims: It has been widely reported that SARS-CoV-2 attaches human cells by using the ACE2 receptor, which is expressed in several organs, including the endothelial cells. Whether vascular impairment described during COVID-19 infection is primarily due to the direct involvement of the endothelial cells by the virus or secondarily to the inflammatory host response is currently unknown, but there is evidence that SARS-CoV-2 can directly infect human blood vessel. We therefore aimed to demonstrate in vivo the presence of endothelial dysfunction in COVID-19 patients without cardiovascular risk factors or pre-existing cardiac conditions.

Methods and results: We used the Endo-Pat 2000, a device able to measure endothelial vasodilation function in a rapid and noninvasive way. The device records endothelium-mediated changes in the digital pulse waveform known as the Peripheral Arterial Tone (PAT) signal, measured with a pair of plethysmographic probes situated on the index finger of both patient’s hands. Endothelium mediated changes in the PAT signal are elicited by creating a downstream hyperemic response, induced by blood flow occlusion in the brachial artery for 5 minutes using an inflatable cuff on one arm. The response to reactive hyperemia is evaluated automatically by the device, and a PAT ratio is calculated using the post- and pre-occlusion PAT values relative to the occluded arm (compared to the measurements from the contralateral arm, which serves as control for non endothelial dependent systemic effects). The Reactive Hyperemia Index (RHI) is then calculated as the ratio of Pulse Wave Amplitude (PWA) measured during the 60-second period after cuff deflation divided by the average PWA measured before cuff inflation; RHI values below 1.67 are suggestive of endothelial dysfunction. We evaluated six patients with laboratory-confirmed SARS-CoV-2 infection with a mean age of 75.8 years. Five of them were female (63.3%); the average mean arterial pressure was 87 mmHg (normal values 70-110 mmHg). Blood sample tests revealed an inflammatory state in all patients, with high plasma levels of C-reactive protein, fibrinogen, ferritin, LDH, and D-dimer. Overall, four patients were positive for endothelial dysfunction, with RHI values between 1.13-1.56 (average value 1.32, normal values >1.67); in one of the two negative patients the reported RHI value was slightly above the cutoff (1.72).

Conclusion: Our findings confirm that COVID-19 patients are at higher risk of developing endothelial dysfunction. In addition, our results demonstrate that endothelial impairment may occur even in the absence of cardiovascular risk factors. Endothelial dysfunction may play a pivotal role in the pathophysiology of the infection process and may identify a subset of patient at a higher risk of worse outcome. In a small series of patients who died from COVID-19, severe endothelial injury associated with intracerebral virus detection, disruption of endothelial cell membranes, widespread pulmonary vascular thrombosis and occlusion of alveolar capillaries with significant new vessel growth, was observed. Early recognition of endothelial impairment at an early stage of the disease appears critical. Whether the evidence of endothelial dysfunction, through noninvasive approaches, can predict worse clinical outcomes or higher risk of thromboembolic events needs to be proven by recruiting a larger number of affected patients. Nevertheless, our results contribute to the knowledge of the pathophysiological mechanisms related to COVID-19 infection.

605 Remote cardiac care in COVID-19 epoch: our experience with V-lap device in advanced heart failure patients

Atilio Restivo1, Giuseppe Princi1, Daniele Rodolico1, Francesco Canonic1, Nadia Aspromonte1, Carlo Trani1, Filippo Crea1, and Domenico Diamario1

Aims: To report our experience with the V-lap device in advanced heart failure patients.

Methods: We treated 12 patients with advanced heart failure admitted to our ward. The V-lap device was used as a liquid ventilation modality in all patients. We compared the echocardiographic findings before and after the insertion of the device.

Results: All patients showed a significant improvement in their clinical status. The mean length of stay in the ICU was 3 days. The mean length of hospitalization was 8 days. The mean length of stay in the hospital was 14 days. The mean length of stay in the hospital was 21 days. The mean length of stay in the hospital was 30 days.

Conclusion: The V-lap device is a feasible and safe option for remote cardiac care in COVID-19 epoch.

The outbreak of COVID-19 has imposed disruptive changes in cardiovascular care worldwide: the usual modalities of care delivery for HF patients have been...
implemented, promoting preventive measures, minimizing in-person contacts, reduc-
ing patients’ and health care providers’ risk of exposure. This unprecedented sce-
nario has accelerated the transition towards telemedicine as a way to provide safe, accountable, and effective care in HF. A paradigmatic example is the chronic HF management through remote telemonitoring of left atrial pressure (LAP) using the V-LAP™ device (Vectorious Medical Technologies), currently tested at our centre under the VECTOR-HF first-in-man clinical study.

The study population consists of patients in NYHA functional class III who have a his-
tory of hospitalization for worsening HF or elevated ambulatory levels of BNP in ter-
nominal pro BNP. The device is implanted under fluoroscopy and TEE-guidance in a trans-septal fashion. Once implanted, the battery-free intracardiac device captures the LAP, that is collected by means of an external belt, sending data to the cardiol-
gist via a cloud-based system. After 90 days, right heart catheterization confirms the accuracy of LAP measurements as compared to pulmonary capillary wedge pressure. Once the reliability is confirmed, LAP can be used to guide optimization of medical therapy.

In our centre, three patients have been enrolled so far: 1) The first V-LAP™ was implanted in Jun 2019 in a 75yo patient with severely reduced LVEF (25%), and frequent HF hospitalizations. At 16 months, NYHA functional class improved (from III to II) along with an amelioration of both the 6-minute walking test and the perceived quality of life, according to KCCQ questionnaire. 2) The second patient is a 70yo patient suffering from HFrEF in dilated ischemic cardiopathy, LVEF 30%, NYHA III, with multiple readmissions for HF worsening. He underwent implantation in Feb 2020. At 8 months, NYHA functional class improved (from III to II). 3) The third patient was implanted in Sep 2020. He is a 65yo patient with non-obstructive hyper-
trophic cardiomyopathy, LVEF 28%, NYHA III, with several HF related hospitalizations. We eagerly wait for his data to be available after 3-months right heart catheteriza-
tion. However, he had no clinical worsening to date.

During the course of COVID-19 pandemic, remote analysis of LAP curves led to earlier detection of underlying disease progression preventing clinical decompensation: when the mean LAP was observed, diuretic therapy was modified accordingly (see example below from first patient). Among our patients, no hospital readmissions occurred over COVID-19 era, avoiding medical contacts and in-hospital exposure. Moreover, the V-LAP™ system showed remarkable reliability and easiness of use, encouraging patients to adhere with a high compliance rate (>99%).

417 Mortality risk assessment using CHA(2)DS(2)-VASc scores in patients hospitalised with COVID-19 infection

Gaetano Ruocco1, Peter McCullough1, Kristen Tescos2, Massimo Mancone1, Gaetano Maria De Ferrari1, Fabrizio D’Accenzo1, Francesco De Rosa1, Anita Peigl1, Giovanni Forleo6, Girol Secco7, Gianfranco Pistis7, Silvia Monticone4, Marco Vicenzi8, Maria De Ferrari4, Fabrizio D’amico6, Pasquale Rastoni9, Daniele Brunetti1, Giovanni Chiariello1, Antonino Fazzolari1, Giovanni Chiariello1, Francesco Santoro1, Ivan Nunez2, Martino Pepe3, and Natalia Daniele Brunetti1

Methods and results: 154 consecutive patients were enrolled in a multicenter inter-
national registry. 12-lead ECG was performed at admission, after 7 and 14 days; QTc values were analyzed. Fifteen (14%) patients developed a prolonged-QTC (pQTc) after 7 days (mean QTc increase > 20ms, +16%, p < 0.001); these patients were older, had higher basal heart rates, higher rates of paroxysmal atrial fibrillation, lower pla-
tel count. QTc increase was inversely proportional to baseline QTc levels and leuko-
cyte count and directly to basal heart rates (p < 0.01). At multivariate stepwise analysis including age, male gender, paroxysmal atrial fibril-
lation, basal QTc values, basal heart rate and dual antiviral therapy, age (OR 1.06, 95% C.I. 1.00-1.13, p < 0.05), basal heart rate (OR 1.07, 95% C.I. 1.02-1.13, p < 0.01) and dual antiviral therapy (OR 12.46, 95% C.I. 2.09-74.20, p < 0.01) were independent predictors of QTc prolongation.

Incidence of LTA during hospitalization was 3.9%. Three pts experienced cardiac arrest and three non-sustained VT. LTAs were recorded after 14 - 7 days from hospi-
talization and were associated with poor outcome with 66% of mortality rate.

288 TC interval prolongation and life-threatening arrhythmias in patients with COVID-19. Results from a multi-centre prospective registry

Francesco Santoro1, Francesco Montillo1, Pasquale Rastoni1, Agostino Lopizzo1, Luigi Di Martino1, Luigi Di Biase1, and Natalia Daniele Brunetti1

Methods and results: 5838 patients were enrolled in a multicenter-international pro-
pective registry (HOPE-COVID19). Demographic and clinical data including drug ther-
apy and in-hospital complications were recorded. 5480 (94%) patients did not receive any AC before hospitalization. In the overall cohort AC therapy during hospitalization was not associated with better survival rate (81 vs 81%, p = 0.94), but with higher risk of bleeding (2.7 vs 1.8%, p = 0.03). Among patients admitted with respiratory failure (49%, n = 2895 pts), AC started dur-
ing hospitalization was associated with lower mortality rates (32 vs 42%, p < 0.01) without increased rates of bleeding (9 vs 8%, p = 0.88), but not in those with non-invasive ventilation (35 vs 38%, p = 0.40).

At multivariate Cox’ analysis mortality relative risk with AC was 0.58 (95% CI 0.49-
0.67) in patients admitted with respiratory failure, 0.50 (95% CI 0.49-0.67) in those requiring invasive ventilation, 0.72 (95% CI 0.51-1.01) in non-invasive ventilation.
Conclusion: AC therapy in general population with COVID-19 is not associated with better survival rates but with higher bleeding risk. Better results can be observed in patients admitted with respiratory failure and requiring invasive ventilation.

166 Exosomal micromas drive pulmonary thromboembolism in Covid-19
Jessica Gambardella1, 3, Celesitno Sarrit2, Paolo Maggi2, Raffaele Martella2, Marco Bruno Merelli2, Vincenzo Maresìa, Giuseppe Paolisso3, Xujun Wang4, and Gaetano Santulli1, 3
1Federico II University—Itme, 2Vanvitelli University, 3Einstein College of Medicine—Montefiore University Hospital

Aims: Thromboembolic events have been shown to play a key role in the outcome of COVID-19. The analysis of the exosomal cargo, including microRNAs (miRNAs), may provide a unique view into relevant diseases or define new diagnostic/prognostic potential. Emerging evidence has shown that exosomal miRNAs are involved in a number of physiologic and pathologic processes. However, neither exosomes nor miRNAs have been hitherto investigated in COVID-19.

Methods and results: To test the hypothesis that exosomal miRNAs are a key determinant of pulmonary thromboembolism (PTE) in COVID-19, we enrolled COVID-19 patients with signs and symptoms suggestive of PTE. The study was approved by the local Ethical Committee and informed consent was obtained. Circulating exosomes were isolated from these patients on admission following established protocols and levels of the top three exosomal miRNAs from a panel to profile human miRNAs were validated by RT-qPCR. Patients were divided in two groups based on the confirmed or non-confirmed diagnosis of PTE, obtained by high-resolution computed tomography and/or angiogram, in order to verify the presence of pulmonary micro/macro-thrombi. When comparing patients with confirmed PTE vs patients without PTE, we found that D-dimer, age, and diabetes mellitus were different (P < 0.05), corroborating the key role of these factors in the pathogenesis of PTE; we also found that levels of exosomal miR-103a, miR-145, and miR-885 were significantly different between these populations. Mechanistically, Tissue Factor has been identified as a direct target of miR-145, while miR-885 targets the von Willebrand Factor. Equally important, low levels of miR-103a have been observed in deep vein thrombosis, although a precise mechanism explaining such a relationship has not been fully defined. An inverse correlation between exosomal miR-145 and D-dimer was also evident (RP: 0.4458, P = 0.0002). Strikingly, using a stepwise multiple regression analysis, correcting for age, diabetes, hypertension, and D-dimer, exosomal miR-145 was confirmed as an independent predictor of PTE [B: -3.140, Wald: 6.047, 95% C.I. for EXP: 0.004-0.529; P = 0.014].

To our knowledge, this is the first study showing an association between exosomal non-coding RNA and PTE in COVID-19 patients. Since endothelial dysfunction has been shown to be a prominent hallmark of COVID-19 and to contribute to the pro-thrombotic and pro-inflammatory state of the vasculature, we speculate that a main source could be represented by endothelial cells and/or platelets, which are known to express miR-145, miR-103a, and miR-885 in normal conditions. Moreover, endothelial cells express the main co-factors required by SARS-CoV-2 to enter the host cells, including angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2).

Conclusion: We identified an unprecedented significant association between exosomal miRNAs and PTE, which could be helpful to better understand the molecular mechanisms underlying PTE pathophysiology, as well as to identify patients who are at risk of developing PTE. Consistent with our findings, in a series of COVID-19 autopsies, PTE has been shown to be a fundamental feature, strongly indicating that thrombosis plays a crucial role in the disease process and in its outcome. Further analyses are warranted to ratify our results and prospectively evaluate their prognostic value.

573 Impact of COVID-19 on ventricular arrhythmias
Marco Silei1, Samuele Principi1, Paolo Compagnucci1, Michela Casella1, Federico Guerra1, and Antonio Dello Russo1
1Università Politecnica delle Marche

Aims: The COVID-19 pandemic has affected the hospital management of many diseases. The rapid spread of the virus and the serious clinical conditions of patients requiring intensive care have caused a reorganization of activities in hospital facilities: in the electrophysiology (EP) laboratory, interventional procedures have been postponed in elective cases, giving priority to clinical emergencies, such as catheter ablation (CA) for electrical storm (ES). As of today, there has been no clear scientific evidence correlating the SARS-CoV-2 infection with fatal or near-fatal arrhythmias, such as ventricular tachycardia (VT) and electrical storm (ES). We sought to evaluate how the numbers of CA for ES and VT have changed in the COVID-19 period, as compared to the pre-COVID-19 era.

Methods and results: We conducted a single-centre, retrospective, observational study. We enrolled two groups of patients undergoing EP procedures of CA for ES and VT at the University Hospital “Ospedali Riuniti” in Ancona, Italy, a tertiary-level referral centre. The first group includes patients undergoing CA for ES and VT in the six months preceding the COVID-19 pandemic (September 9, 2019-March 8, 2020). The second group includes patients undergoing the same procedures in the first six months of the COVID-19 emergency (March 9, 2020-September 9, 2020). March 9, 2020 was chosen to mark the beginning of the COVID-19 era because this was the day when novel health care measures were taken in the cardiology department of our hospital. Each subject in Group B was evaluated with polymerase chain reaction (PCR) tests for SARS-CoV-2 on throat swabs before CA procedures. We enrolled 40 patients undergoing CA procedures for ES and VT. More CA procedures were performed during the COVID-19 period, as compared to the pre-COVID-19 period (27 vs 13 patients). This difference was mainly driven by an increase in CA for ES during the COVID-19 period (16 vs 7). Furthermore, PCR tests for SARS-CoV-2 on throat swabs were negative in all patients.

Conclusion: Our data suggest that, during the COVID-19 emergency, there was an increase of non-deferrable EP procedures, such as CA for ES. Although we suppose two possible explanations. Firstly, the COVID-19 emergency may have worsened the assistance to patients with chronic diseases, both due to the channeling of resources in the COVID-19 emergency and to the need to minimize interpersonal contacts, including non-urgent visits; this may have indirectly facilitated the development of ES. Secondly, despite the negative results of SARS-CoV-2 throat swabs, a previous COVID-19 cannot be completely ruled out, raising the possibility that the virus may have also acted directly, setting the stage for ES. Further studies are needed in order to examine in depth the multiple possible relationships between COVID-19 and arrhythmogenesis.

88 Severe COVID-19 in a patient with late presentation stemi: a double-edged sword
Giorgio Sofia1, Massimo Volpe1, Allegra Battistoni1, Simone Reale1, Sara Corradetti1, and Enrico Rathina Raj1
1Università “La Sapienza di Roma, Facolta’ di Medicina e Psicologia

Although the emergent COVID-19 is usually dominated by respiratory symptoms, COVID-19 patients may also develop cardiovascular complications, which may even become the ultimate cause of death. Indeed, several studies have been reported a strict correlation between SARS-CoV-2 infection and the increase of mortality and morbidity in cardiovascular patients. Moreover, the late presentation and management of acute coronary syndromes due to the fear of being infected in healthcare structures during this pandemic have led to worse cardiovascular outcomes. A 62-year-old man with no previous disease, admitted with respiratory failure caused by SARS-CoV-2 interstitial pneumonia (Fig. 1), incurred in a cardiogenic shock due to a severe left ventricular dysfunction with several episodes of sustained ventricular tachycardia. The EKG showed Q-waves with ST-segment elevation as for a late presentation STEMI (Fig. 2) and the echocardiogram confirmed left ventricle dysfunction and septal-apical aneurism (Fig. 3). As soon as the patients could speak, he referred an episode of angina a couple of weeks before the admission to the hospital, but he avoided seeking help because afraid of being exposed to SARS-CoV-2 in healthcare structures. The in-hospital management of this patient has been challenging. Despite a complete coronary revascularization of the left anterior descending artery, the patient had to undergo a defibrillator implantation in secondary prevention and his prognosis remained poor due to the several impairment of left ventricular ejection fraction and the lung interstitial fibrosis.

From this single case, two major lessons can be learned: (1) the course of COVID-19 may be complicated by concomitant critical cardiovascular conditions, such as a recent acute myocardial infarction; (2) late presentation and management of acute myocardial infarction may be the consequence of the fear of the contagion during a pandemic. Therefore there is need for a specific health protocol for acute condition in the perspective of a new pandemic phase.
Aims: Italy has been profoundly hit by the SARS-COV-2 pandemic. As a result, governa-
tive measures were required to slow down the spread, with a lockdown imposed beginning from March to June 2020. Such measures involved also in-hospital outpatient visits, and clinicians were urged to postpone or even halt visits deemed as non-urgent.

Methods and results: At the beginning of COVID-19 lockdown (from March 9th through out May 15th) the already existing tele-health monitoring programme of the Hypertrophic Cardiomyopathy (HCM) Outpatient Clinic at the Ospedale Policlinico San Martino, in Genova, Italy, was implemented. HCM and cardiac amyloid (CA) patients with a sched- uled visit were contacted by a medical trainee to assess urgency related to her/his medi-
cal evaluation. According to information collected via the tele-medical contact, patients were divided in ‘stable’ (group A) and ‘potentially unstable’ (group B). Patients were deemed as ‘potentially unstable’ if one or more of the following were present: signs and/or symptoms of heart failure (HF), in particular if worsening relatively to the base-
line condition; known end-stage HCM; HF hospitalization(s) or multiple (≥3) outpatient evaluations in the prior 6 months. Those in group B received weekly tele-medical contact to monitor their conditions and evaluate the need for in-hospital in-person visits, whereas those in group A were scheduled to be contacted after 1 month. In the observation period, 40 patients (median age: 62 years, 28 HCM and 12 CA patients) received a tele-
contact. In 15 cases the tele-medical contact was pursued via email. Nineteen patients were deemed as ‘potentially unstable’ (10 CA and 9 HCM). The main reason for inclusion in group B was a recent HF hospitalization. No ‘stable’ patients sought medical attention outside the planned tele-medical contacts. Eight ‘potentially unstable’ patients needed unplanned medical attention. In 4 instances, their need were managed via tele-contact without the need for in-person evaluations: 2 CA patients needed optimization of diuretic therapy; 2 obstructive HCM patients needed optimization of therapy for relief of obstruc-
tion. In 3 other instances, a medical outpatient evaluation was required: 2 CA patients presented worsening HF symptoms, and 1 severely obese HCM patient presented a new-
 onset atrial fibrillation with high ventricular response. Finally, 1 CA patient required hos-
pitalization due to acute decompensated HF.

Conclusion: Tele-health monitoring strategies have never been specifically assessed in cardiomyopathy patients. In our experience, a short-term tele-health monitoring programme was feasible and effective. In current COVID-19 times, tele-medicine served as an emergency tool, yet lessons from its beneficial impact on healthcare practice may be exploited for the future.

22 Prognostic utility of quantitative offline 2D-echocardiography in hospitalized patients with COVID-19 disease
Filippo Toriello1, Francesca Bursi1, Gloria Santangelo1, Dario Sansalone1, Federica Vali1, Anna Maria Vella1, Andrea Barbieri2, and Stefano Carugol
Division of Cardiology, Heart and Lung Department, San Paolo Hospital, Assi Sante Paolo and Carlo, University of Milan, 1Division of Cardiology, Department of Diagnostics, Clinical and Public Health Medicine, Policlinico University Hospital of Modena, University of Modena and Reggio Emilia

Aims: To assess the prognostic utility of quantitative 2-D-echocardiography, including strain, in patients with confirmed COVID-19 disease.

Methods and results: COVID-19 patients admitted to the San Paolo University Hospital of Milan, that underwent a clinically indicated echocardiographic exam were included in the study. To limit contamination all measurements were performed offline. Quantitative measurements were obtained by an operator blinded to the clinical data. Among the 49 patients, non-survivors (33%) had worse respiratory parameters, index of multiorgan failure and worse markers of severity of lung involvement. Right Ventricular (RV) dysfunction (as assessed by conventional and 2- dimensional speckle tracking) was a common finding and a powerful independent predictor of mortality. At the ROC curve analyses, RV free-wall (FW) longitudinal strain (L) showed an AUC 0.77 ± 0.08 in predicting death, p = 0.008, and global RV LS (RV-GLS) showed an AUC 0.79 ± 0.04, p = 0.004. This association remained significant after correction for age (OR = 1.16, 95%CI 1.01-1.34, p = 0.029 for RV-FW LS and OR = 1.20, 95%CI 1.01-1.42, p = 0.033 for RV-GLS), for oxygen partial pressure at arterial gas analysis/fraction of inspired oxygen (OR = 1.27, 95%CI 1.04-1.57, p = 0.021 for RV free-wall LS and OR = 1.30, 95%CI 1.04-1.62, p = 0.020 for RV-GLS) and for the severity of pulmonary involvement measured by a computed tomography lung score (OR = 1.27, 95%CI 1.02-1.19, p = 0.034 for RV free-wall LS, and OR = 1.30, 95%CI 1.04-1.63, p = 0.022 for RV-GLS).

Conclusion: In patients hospitalized with COVID-19, offline quantitative 2D-echocar-
diographic assessment of cardiac function is feasible. Parameters of RV function are frequently abnormal and have an independent prognostic value over markers of severity of pulmonary involvement.